Vaccine Safety Registry
Hib Vaccine Safety
Institutional safety data for Haemophilus influenzae type b (Hib) vaccines. Clinical monitoring, manufacturer packages, and adverse event profiles.
Medically reviewed by
Dr. Aarti Ghosh, MBBS, MD (General Medicine), DM (Clinical Immunology)
View Clinical ProfileOpen Access Clinical Intelligence for All Readers
HCP Connect provides publicly accessible vaccine-safety information for healthcare professionals, patients, caregivers, researchers, and the wider public. Access to this Vaccine Safety Monograph does not require an account, registration, or NPI verification.
Translate this vaccine safety monograph into your preferred language:
Automated translation provided for accessibility · English version is the authoritative clinical record.
Clinical Overview
Professional summary
Haemophilus influenzae type b (Hib) is a virulent bacterium responsible for severe invasive diseases, including bacterial meningitis, pneumonia, and acute epiglottitis. Prior to the introduction of the registry vaccines, Hib was the primary driver of bacterial meningitis in children under 5 years of age.
Contemporary immunization has resulted in a 99% reduction in disease incidence. These conjugate modules met all clinical safety and efficacy criteria established by the Food and Drug Administration (FDA).
Vaccine Formulations
Module specifics & formulations
Formulation Node
Single-Antigen Modules
Ages: 2 months - 5 years
- ActHIB (Sanofi)
- Hiberix (GSK)
Formulation Node
Combination Protocols
Multivalent series
- Pentacel (Sanofi)
- Vaxelis (MCM)
Clinical Triage
Eligibility & contraindications
Absolute & Relative Contraindications
- Anaphylaxis to previous Hib series dose
- Acute moderate-to-severe illness state
- Pediatric age below 6 weeks
Adverse Events
Reported reactions & surveillance
Local Reactions
- Localized erythema (Redness)
- Thermal induration (Warmth)
- Injection site swelling
Systemic Reactions
- Low-grade pyrexia (Fever)
- Generalized lethargy
- Minor irritability
Surveillance Analytics
Post-market surveillance metrics
35+ Years
Surveillance Data
99%
Reduction in Incidence
Institutional Synthesis
Continuous active surveillance confirms that Hib vaccination benefits far outweigh statistically minimal risks, maintaining an exemplary safety profile across all pediatric cohorts.
Editorial Governance
Clinical Reviewers & Authors
Dr. Aarti Ghosh
MBBS, MD (General Medicine), DM (Clinical Immunology)
Clinical Immunology
All vaccine safety monographs are authored and reviewed by credentialed medical specialists in infectious disease, immunology, and pediatrics.
Browse All Clinical Authors & Medical Reviewers DirectoryEvidence Base
Sources & References
The clinical guidance, contraindications, and safety surveillance statistics in this monograph are synthesized directly from authoritative public health agencies, regulatory package inserts, and peer-reviewed clinical studies:
- 1CDC2024Prevention and Control of Haemophilus influenzae Type b Disease: Recommendations of the ACIP
MMWR Recommendations and Reports, 63(RR01):1-14
- 2WHO2024Haemophilus influenzae type b (Hib) vaccine: WHO position paper
Weekly Epidemiological Record, 88(39):413-428
- 3FDA2024ACTHIB, HIBERIX, and PEDVAXHIB Package Inserts & Post-Licensure Safety Reviews
U.S. Food and Drug Administration CBER
Cite & Reference This Monograph
Content Licensing & Governance
Content Licensing & Reuse Policy
HCP Connect. Content licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0). See our Content Licensing & Reuse Policy for details.
Authored by Dr. Aditya Kumar and clinically reviewed by Dr. Aarti Ghosh, in alignment with HCP Connect Clinical Faculty & Reviewers Directory. Content verified against 2026 CDC ACIP and WHO SAGE safety protocols.
Vaccine Safety Enquiries & Direct Response
HCP Connect welcomes clinical questions, public health inquiries, and feedback regarding our vaccine safety monographs. Our clinical editorial staff and medical reviewers actively monitor all incoming communications.
Guaranteed Enquiry Response Timeline
We commit to responding in writing to all clinical and public enquiries within 2–3 business days (guaranteed within 5 calendar days, well within the 10 calendar day international assessment standard). Urgent clinical sourcing corrections are triaged within 24 hours.